GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 359.71 Thousand USD | 2538.14% |
| 2022 | 13.63 Thousand USD | -86.39% |
| 2021 | 100.17 Thousand USD | 36.04% |
| 2020 | 73.63 Thousand USD | 452.15% |
| 2019 | 13.33 Thousand USD | -93.11% |
| 2018 | 193.68 Thousand USD | 159.31% |
| 2017 | 74.69 Thousand USD | -85.55% |
| 2016 | 516.89 Thousand USD | 394.15% |
| 2015 | 104.6 Thousand USD | -59.04% |
| 2014 | 255.39 Thousand USD | 596.05% |
| 2013 | -51.48 Thousand USD | -115.71% |
| 2012 | 327.69 Thousand USD | 5309.23% |
| 2011 | 6058.00 USD | 167.9% |
| 2010 | -8922.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 329 Thousand USD | 0.18% |
| 2024 Q1 | 368.67 Thousand USD | 2.49% |
| 2024 Q2 | 328.4 Thousand USD | -10.92% |
| 2023 FY | 359.71 Thousand USD | 2538.14% |
| 2023 Q2 | 59.47 Thousand USD | 384.43% |
| 2023 Q3 | 15.87 Thousand USD | -73.3% |
| 2023 Q4 | 359.71 Thousand USD | 2165.46% |
| 2023 Q1 | 12.27 Thousand USD | -9.96% |
| 2022 Q2 | 19.42 Thousand USD | -92.09% |
| 2022 FY | 13.63 Thousand USD | -86.39% |
| 2022 Q4 | 13.63 Thousand USD | -31.78% |
| 2022 Q1 | 245.45 Thousand USD | 145.04% |
| 2022 Q3 | 19.98 Thousand USD | 2.9% |
| 2021 Q4 | 100.17 Thousand USD | 46.8% |
| 2021 FY | 100.17 Thousand USD | 36.04% |
| 2021 Q2 | -39.89 Thousand USD | -144.83% |
| 2021 Q1 | 89 Thousand USD | 20.87% |
| 2021 Q3 | 68.23 Thousand USD | 271.02% |
| 2020 Q4 | 73.63 Thousand USD | 17.12% |
| 2020 FY | 73.63 Thousand USD | 452.15% |
| 2020 Q3 | 62.87 Thousand USD | 8.94% |
| 2020 Q2 | 57.71 Thousand USD | -13.74% |
| 2020 Q1 | 66.9 Thousand USD | 401.7% |
| 2019 Q1 | 175.5 Thousand USD | -9.39% |
| 2019 Q3 | 66.21 Thousand USD | -62.37% |
| 2019 Q4 | 13.33 Thousand USD | -79.86% |
| 2019 Q2 | 175.95 Thousand USD | 0.26% |
| 2019 FY | 13.33 Thousand USD | -93.11% |
| 2018 Q2 | 119.33 Thousand USD | 34.78% |
| 2018 Q4 | 193.68 Thousand USD | 122.05% |
| 2018 Q1 | 88.54 Thousand USD | 18.54% |
| 2018 FY | 193.68 Thousand USD | 159.31% |
| 2018 Q3 | 87.22 Thousand USD | -26.91% |
| 2017 Q2 | 543.3 Thousand USD | 7.67% |
| 2017 FY | 74.69 Thousand USD | -85.55% |
| 2017 Q3 | 591.17 Thousand USD | 8.81% |
| 2017 Q1 | 504.6 Thousand USD | 0.0% |
| 2017 Q4 | 74.69 Thousand USD | -87.37% |
| 2016 Q1 | 147.78 Thousand USD | 41.28% |
| 2016 Q2 | 241.1 Thousand USD | 63.14% |
| 2016 Q4 | - USD | -100.0% |
| 2016 FY | 516.89 Thousand USD | 394.15% |
| 2016 Q3 | 415.7 Thousand USD | 72.42% |
| 2015 Q1 | 294.18 Thousand USD | 15.19% |
| 2015 Q3 | 263.3 Thousand USD | 24.03% |
| 2015 Q2 | 212.29 Thousand USD | -27.84% |
| 2015 FY | 104.6 Thousand USD | -59.04% |
| 2015 Q4 | 104.6 Thousand USD | -60.27% |
| 2014 FY | 255.39 Thousand USD | 596.05% |
| 2014 Q4 | 255.39 Thousand USD | 8.04% |
| 2014 Q3 | 236.38 Thousand USD | 264.3% |
| 2014 Q2 | 64.88 Thousand USD | -51.28% |
| 2014 Q1 | 133.17 Thousand USD | 358.67% |
| 2013 Q1 | 15.56 Thousand USD | -95.25% |
| 2013 Q2 | -21.12 Thousand USD | -235.71% |
| 2013 Q3 | -164.99 Thousand USD | -681.08% |
| 2013 Q4 | -51.48 Thousand USD | 68.8% |
| 2013 FY | -51.48 Thousand USD | -115.71% |
| 2012 Q2 | 366.75 Thousand USD | 431.69% |
| 2012 FY | 327.69 Thousand USD | 5309.23% |
| 2012 Q4 | 327.69 Thousand USD | -37.32% |
| 2012 Q3 | 522.78 Thousand USD | 42.54% |
| 2012 Q1 | 68.97 Thousand USD | 1038.64% |
| 2011 Q3 | -23.34 Thousand USD | -613.6% |
| 2011 Q2 | -3271.00 USD | 39.67% |
| 2011 Q1 | -5422.00 USD | 0.0% |
| 2011 FY | 6058.00 USD | 167.9% |
| 2011 Q4 | 6058.00 USD | 125.95% |
| 2010 FY | -8922.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.159% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 42.203% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 244.103% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1862.593% |
| Qrons Inc. | 351.42 Thousand USD | -2.357% |
| Rebus Holdings, Inc. | 305 Thousand USD | -17.938% |
| Skye Bioscience, Inc. | -5.72 Million USD | 106.287% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 105.706% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.172% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -1710.59% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 93.632% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 27558.779% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 97.718% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 91.265% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 10.486% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.993% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 83.958% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 61.204% |
| Mesoblast Limited | 55.85 Million USD | 99.356% |
| Marizyme, Inc. | 18.56 Million USD | 98.063% |
| Genus plc | 190.6 Million USD | 99.811% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 83.912% |
| Pharming Group N.V. | 109.8 Million USD | 99.672% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 58.185% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 70.367% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 47.101% |
| ContraFect Corporation | -6.02 Million USD | 105.969% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -167.166% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 68.868% |
| IMV Inc. | 7.67 Million USD | 95.31% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 93.462% |
| MultiCell Technologies, Inc. | 90.04 USD | -399400.222% |
| ONE Bio Corp. | 9.04 Million USD | 96.021% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 149.008% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 97.221% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 73.705% |
| Q BioMed Inc. | 4.06 Million USD | 91.14% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 98.823% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 64.304% |
| Biomind Labs Inc. | 711.4 Thousand USD | 49.436% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.406% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 82.009% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 97.191% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -157.296% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 83.664% |
| GB Sciences, Inc. | 1.74 Million USD | 79.414% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 295.72% |
| HST Global, Inc. | 96.79 Thousand USD | -271.628% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -74.433% |
| Halberd Corporation | 144.72 Thousand USD | -148.554% |
| Enzolytics Inc. | 981.65 Thousand USD | 63.357% |
| Agentix Corp. | 37.63 Thousand USD | -855.887% |
| Resverlogix Corp. | 6.45 Million USD | 94.424% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 153.442% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.018% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.765% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 94.913% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 86.72% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 104.069% |
| AVAX Technologies, Inc. | -5.9 Million USD | 106.093% |
| Zenith Capital Corp. | 10.06 Thousand USD | -3474.225% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.034% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -79.467% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 84.924% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -118.657% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 2063.697% |
| Kadimastem Ltd | -253.1 Thousand USD | 242.121% |
| Helix BioMedix, Inc. | -2.57 Million USD | 113.996% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 98.226% |
| BioStem Technologies, Inc. | 4.47 Million USD | 91.956% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -78.734% |
| LadRx Corporation | -2.03 Million USD | 117.663% |
| Cell Source, Inc. | 9.23 Million USD | 96.104% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 43.368% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 43.368% |
| NovAccess Global Inc. | 2.17 Million USD | 83.488% |
| Affymax, Inc. | -5.59 Million USD | 106.427% |
| Itoco Inc. | 228.3 Thousand USD | -57.557% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -164.514% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 92.743% |
| Mobile Lads Corp. | 484.23 Thousand USD | 25.715% |
| CytoDyn Inc. | 20.26 Million USD | 98.225% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 55696.6% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 3981.062% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 95.332% |
| SYBLEU INC | 473.71 Thousand USD | 24.066% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 91.929% |
| International Stem Cell Corporation | 2.59 Million USD | 86.112% |
| Bioxytran, Inc. | 1.89 Million USD | 81.057% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -476.338% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 83.506% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 89.525% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 95.794% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 53.442% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 128.777% |
| Neutra Corp. | 52.18 Thousand USD | -589.271% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 114.452% |
| PureTech Health plc | -167.19 Million USD | 100.215% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 246.876% |
| IXICO plc | -4.44 Million USD | 108.093% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 97.279% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.344% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Cellectis S.A. | -43.81 Million USD | 100.821% |